MAT Tools and Resources

This Topic Brief provides information on the impact of the COVID-19 pandemic on the behavioral health of the general public and healthcare workers, the impact of substance use disorders on COVID-19 outcomes, and other topics.

This Topic Brief aims to provide practical information and resources for using telehealth technologies to implement patient-centered integrated behavioral health care in primary and ambulatory care practices, including those related to substance use.

This brief assesses whether and how rates of substance use and substance use disorder among adults differ by race and ethnicity using five years of data, 2015-2019, from the National Survey on Drug Use and Health.

This publication is intended to aid policymakers, communities, and key stakeholders in developing comprehensive, multi-system strategies that address the opioid crisis.

This web page is a resource center for social media, video, print, radio, FAQs, messaging, and other marketing materials that can be used to promote the 988 Suicide & Crisis Lifeline. It is designed for states, territories, tribes, crisis centers, communities, emergency service providers, and other partners to speak with one voice.

This guideline provide evidence-based strategies and standards of care for the treatment of stimulant use disorders, stimulant intoxication, and stimulant withdrawal, as well as secondary and tertiary prevention of harms associated with stimulant use.

This toolkit is a resource for Peer Recovery Specialists (PRSs) to feel equipped to discuss MOUD with providers, people seeking recovery, and others with questions about this treatment option.

This SAMHSA Advisory outlines the principles and components of low barrier care and how low barrier care may be leveraged to overcome substantial gaps in access, while also engaging individuals in treatment.

This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research.

This virtual public meeting which explored real-world experiences and scientific evidence for buprenorphine initiation strategies, as well as medication dosing and management during continued treatment across different care settings